Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine

NCT02806687 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT02806687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02806687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine
Lead sponsor
University Hospital, Toulouse
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2017
Completion date
June 30, 2022
Enrollment
68 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma